BeyondSpring Inc. (BYSI) |
|
2.53 -0.03 (-1.17%)
|
01-27 16:00 |
|
Open: |
2.55 |
Pre. Close: |
2.56 |
|
High:
|
2.67 |
Low:
|
2.5 |
|
Volume:
|
161,345 |
Market Cap:
|
98(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:10 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 3.49 One year: 4.07 |
| Support: |
Support1: 2.01 Support2: 1.41 |
| Resistance: |
Resistance1: 2.99 Resistance2: 3.49 |
| Pivot: |
2.31 |
| Moving Average: |
MA(5): 2.62 MA(20): 2.19
MA(100): 1.23 MA(250): 1.58  |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 67.7 %D(3): 73.1 |
| RSI: |
RSI(14): 62.2 |
| 52-week: |
High: 3.31 Low: 0.54 |
| Average Vol(K): |
3-Month: 1,034 (K) 10-Days: 543 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BYSI ] has closed below upper band by 32.6%. Bollinger Bands are 70.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.67 - 2.69 |
2.69 - 2.71 |
|
Low:
|
2.45 - 2.48 |
2.48 - 2.5 |
|
Close:
|
2.5 - 2.53 |
2.53 - 2.55 |
|
Company Description |
|
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York. |
Headline News |
Wed, 25 Jan 2023
CapitalGainsReport: Biotech Stocks To Watch in 2023: PBIO, BYSI ... - Marketscreener.com
Thu, 19 Jan 2023
Healthcare Stocks on the Move Thursday: NRSN, PBIO, BYSI, SY, SRDX, TCBP, OLK, ABSI - InvestorsObserver
Thu, 19 Jan 2023
Buyers Jump Aside as Stocks Continue to Fall - RealMoney
Thu, 12 Jan 2023
Do Analysts Agree Thursday on Beyondspring Inc (BYSI) Stock's Target Price? - InvestorsObserver
Tue, 10 Jan 2023
BeyondSpring regains Nasdaq compliance on minimum bid price ... - Seeking Alpha
Tue, 03 Jan 2023
Morningstar's Best- and Worst-Performing Stocks: 2022 - Morningstar
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
2.309e+007 (%) |
|
% Held by Institutions
|
40.5 (%) |
|
Shares Short
|
2,400 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-6.618e+007 |
|
EPS Est Next Qtl
|
-0.55 |
|
EPS Est This Year
|
-3.77 |
|
EPS Est Next Year
|
-3.1 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-4 |
|
Return on Assets (ttm)
|
903 |
|
Return on Equity (ttm)
|
-41.7 |
|
Qtrly Rev. Growth
|
1.35e+006 |
|
Gross Profit (p.s.)
|
95.43 |
|
Sales Per Share
|
-125.45 |
|
EBITDA (p.s.)
|
1.46739e+006 |
|
Qtrly Earnings Growth
|
-1.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-47 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.03 |
|
Price to Cash Flow
|
3.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.93e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
